Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18) - Archive ouverte HAL Accéder directement au contenu
Communication Dans Un Congrès Année : 2017

Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18)

Dates et versions

hal-01626269 , version 1 (30-10-2017)

Identifiants

Citer

J. Bennouna, S. Hiret, C. Borg, A. Bertaut, O. Bouché, et al.. Bevacizumab (Bev) or cetuximab (Cet) plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wild-type (WT) KRAS metastatic colorectal cancer (mCRC): Final analysis of a French randomized, multicenter, phase II study (PRODIGE 18). ESMO 2017 Congress, Sep 2017, Madrid, Spain. pp.477O, ⟨10.1093/annonc/mdx393.004⟩. ⟨hal-01626269⟩
113 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More